131 related articles for article (PubMed ID: 35934607)
1. Re: Inadequacy of PCR genotyping in advanced non-small cell lung cancer: EGFR L747_A755delinsSS Exon 19 deletion is not detected by the real-time PCR IdyllaTM EGFR mutation test but is detected by ctDNA NGS and responds to osimertinib.
Bennett P; Finall A; Medeiros F; Gerrard G; Taniere P
Eur J Cancer; 2022 Oct; 174():315-317. PubMed ID: 35934607
[No Abstract] [Full Text] [Related]
2. Response to letter entitled: Re: 'Inadequacy of PCR genotyping in advanced non-small cell lung cancer: EGFR L747_A755delinsSS exon 19 deletion is not detected by the real-time PCR Idylla
O'Sullivan H; d'Arienzo PD; Yousaf N; Cui W; Popat S
Eur J Cancer; 2022 Oct; 174():318-320. PubMed ID: 35948502
[No Abstract] [Full Text] [Related]
3. Inadequacy of PCR genotyping in advanced non-small cell lung cancer: EGFR L747_A755delinsSS exon 19 deletion is not detected by the real-time PCR Idylla™ EGFR mutation test but is detected by ctDNA next generation sequencing and responds to osimertinib.
O'Sullivan H; d'Arienzo PD; Yousaf N; Cui W; Popat S
Eur J Cancer; 2022 May; 166():38-40. PubMed ID: 35276501
[No Abstract] [Full Text] [Related]
4. The role of comprehensive analysis with circulating tumor DNA in advanced non-small cell lung cancer patients considered for osimertinib treatment.
Sueoka-Aragane N; Nakashima C; Yoshida H; Matsumoto N; Iwanaga K; Ebi N; Nishiyama A; Yatera K; Kuyama S; Fukuda M; Ushijima S; Umeguchi H; Harada D; Kashiwabara K; Suetsugu T; Fujimoto N; Tanaka F; Uramoto H; Yoshii C; Nakatomi K; Koh G; Seki N; Aoe K; Nosaki K; Inoue K; Takamori A; Kawaguchi A
Cancer Med; 2021 Jun; 10(12):3873-3885. PubMed ID: 33982444
[TBL] [Abstract][Full Text] [Related]
5. Circulating tumor DNA analysis of EGFR-mutant non-small cell lung cancer patients receiving osimertinib following previous tyrosine kinase inhibitor treatment.
Beagan JJ; Bach S; van Boerdonk RA; van Dijk E; Thunnissen E; van den Broek D; Weiss J; Kazemier G; Pegtel DM; Bahce I; Ylstra B; Heideman DAM
Lung Cancer; 2020 Jul; 145():173-180. PubMed ID: 32460198
[TBL] [Abstract][Full Text] [Related]
6. Predicting osimertinib-treatment outcomes through EGFR mutant-fraction monitoring in the circulating tumor DNA of EGFR T790M-positive patients with non-small cell lung cancer (WJOG8815L).
Sakai K; Takahama T; Shimokawa M; Azuma K; Takeda M; Kato T; Daga H; Okamoto I; Akamatsu H; Teraoka S; Ono A; Ohira T; Yokoyama T; Yamamoto N; Nakagawa K; Nishio K
Mol Oncol; 2021 Jan; 15(1):126-137. PubMed ID: 33131198
[TBL] [Abstract][Full Text] [Related]
7. Patients with uncommon EGFR mutations also benefit from first-line osimertinib.
Romero D
Nat Rev Clin Oncol; 2024 Feb; 21(2):84. PubMed ID: 38057403
[No Abstract] [Full Text] [Related]
8. Clearing of circulating tumour DNA predicts clinical response to osimertinib in EGFR mutated lung cancer patients.
Boysen Fynboe Ebert E; McCulloch T; Holmskov Hansen K; Linnet H; Sorensen B; Meldgaard P
Lung Cancer; 2020 May; 143():67-72. PubMed ID: 32213382
[TBL] [Abstract][Full Text] [Related]
9. Brief Report: Evaluation of Molecular Profiling Strategies for Neoadjuvant Osimertinib in Stage IIIA EGFR-Mutant NSCLC.
Lu K; Woodward BD; Boys J; Onaitis M; Husain H
Clin Lung Cancer; 2024 Jan; 25(1):e58-e61. PubMed ID: 37852849
[No Abstract] [Full Text] [Related]
10. Osimertinib in Patients With Non-Small Cell Lung Cancer and Uncommon EGFR Mutations-Chasing Unicorns?
Wang VE; Gainor JF
JAMA Oncol; 2024 Jan; 10(1):52-53. PubMed ID: 37991771
[No Abstract] [Full Text] [Related]
11. A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2.
Park CK; Cho HJ; Choi YD; Oh IJ; Kim YC
Cancer Res Treat; 2019 Apr; 51(2):777-787. PubMed ID: 30189719
[TBL] [Abstract][Full Text] [Related]
12. Correspondence to: Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study.
Moik F; Riedl JM; Ay C
Ann Oncol; 2024 Mar; 35(3):327. PubMed ID: 38092622
[No Abstract] [Full Text] [Related]
13. Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M.
Wang Y; Zheng R; Hu P; Zhang Z; Shen S; Li X
BMC Cancer; 2021 Nov; 21(1):1215. PubMed ID: 34774017
[TBL] [Abstract][Full Text] [Related]
14. Analysis of circulating tumour DNA to identify patients with epidermal growth factor receptor-positive non-small cell lung cancer who might benefit from sequential tyrosine kinase inhibitor treatment.
Provencio M; Serna-Blasco R; Franco F; Calvo V; Royuela A; Auglytė M; Sánchez-Hernández A; de Julián Campayo M; García-Girón C; Dómine M; Blasco A; Sánchez JM; Oramas J; Bosch-Barrera J; Sala MÁ; Sereno M; Ortega AL; Chara L; Hernández B; Padilla A; Coves J; Blanco R; Balsalobre J; Mielgo X; Bueno C; Jantus-Lewintre E; Molina-Vila MÁ; Romero A
Eur J Cancer; 2021 May; 149():61-72. PubMed ID: 33831609
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy and Osimertinib Combination Should Not Be the First-Line Treatment for All Advanced EGFR+ NSCLC.
Lim SM; Lee JB; Cho BC
J Thorac Oncol; 2024 Mar; 19(3):376-379. PubMed ID: 38453325
[No Abstract] [Full Text] [Related]
16. Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer.
van Veggel B; Madeira R Santos JFV; Hashemi SMS; Paats MS; Monkhorst K; Heideman DAM; Groves M; Radonic T; Smit EF; Schuuring E; van der Wekken AJ; de Langen AJ
Lung Cancer; 2020 Mar; 141():9-13. PubMed ID: 31926441
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy and Osimertinib Combination Should Be the First-Line Treatment for All Advanced EGFR+ NSCLC.
Chen LN; Lee ATM; Nagasaka M; Ou SI
J Thorac Oncol; 2024 Mar; 19(3):380-384. PubMed ID: 38453326
[No Abstract] [Full Text] [Related]
18. Non-small cell lung cancer harboring EGFR G724S mutation and exon 19 deletion responded to afatinib monotherapy after multiple lines of target therapies.
Cortiula F; Pelizzari G; Corvaja C; De Maglio G; Fasola G
Anticancer Drugs; 2022 Oct; 33(9):960-962. PubMed ID: 35979997
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer.
Papadimitrakopoulou VA; Han JY; Ahn MJ; Ramalingam SS; Delmonte A; Hsia TC; Laskin J; Kim SW; He Y; Tsai CM; Hida T; Maemondo M; Kato T; Jenkins S; Patel S; Huang X; Laus G; Markovets A; Thress KS; Wu YL; Mok T
Cancer; 2020 Jan; 126(2):373-380. PubMed ID: 31769875
[TBL] [Abstract][Full Text] [Related]
20. Longitudinal Circulating Tumor DNA Modeling to Predict Disease Progression in First-Line Mutant Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer.
Johnson M; Serra Traynor C; Vishwanathan K; Overend P; Hartmaier R; Markovets A; Chmielecki J; Mugundu GM; Barrett JC; Tomkinson H; Ramalingam SS
Clin Pharmacol Ther; 2024 Feb; 115(2):349-360. PubMed ID: 38010260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
